Publication
Main pulmonary artery enlargement during bevacizumab therapy in KRAS-mutant metastatic colon cancer.
Mehmet Fatih Ozbay, Fikret Atlım, Sertac Vurgun, Mehmet Hunur, Ayse Keven, Eren Sahin, Sema Sezgin Göksu, Mustafa Karaca
Cancer chemotherapy and pharmacologySep 17, 2026PMID 42752894doi:10.1007/s00280-026-04953-2 Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
PURPOSE: Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is a cornerstone of metastatic colorectal cancer treatment. While systemic hypertension is a recognized complication of VEGF pathway inhibition, the effects of bevacizumab on the pulmonary vasculature…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Colon Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.